We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Established in 2013, OPM Biosciences is an integrated solution provider of cell culture media (CCM) and CDMO service. Our management system is certificated by TÜV NORD as per ISO9001:2015. OPM has 4 facilities of an overall area of 18,000m² operated under full cGMP guidance, along with 2 new facilities of 30000m² under construction.
OPM’s world-class cell culture solution leads to the company’s fast growth. As the first listed CCM company in China, OPM is becoming a leading total solution provider in biologics development and a strategic partner of biopharmaceutical companies worldwide.
OPM CCM business unit offers innovative chemically-defined/serum-free media design and manufacturing. We provide proprietary off-the-shelf commercial media, customized media for clients’ cell lines and OEM service. The unparalleled performance has made us the medium supplier for 110+ biologics (IND or BLA) all over the world.
OPM CDMO service offers efficient End-to-End solutions for biotherapeutic protein development and manufacturing. Our CDMO facilities are operated under cGMP guidance to serve different stages of biologics development, from antibody discovery to IND and BLA manufacturing of up to 2000L. OPM’s meticulous service and our experienced scientists have contributed to the development of 200+ biologics, and have proven records in supporting our global clients to accomplish IND applications at FDA and NMPA in US and China.